Innate Pharma SA (IPHA)
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products i...
- Open
- 2.260
- High
- 2.290
- Low
- 2.220
- Prev. Close
- 2.230
- Volume
- 11.80K
- Turnover
- 26.55K
- Avg Price
- 2.250
- Bid/Ask Ratio
- --
- Amplitude
- 3.14%
- 52wk High
- 2.710
- Volume Ratio
- 4.08
- Turnover Ratio
- 0.02%
Innate Pharma SA Analyst Rating
View moreForecast & Rating
Aug 11, 2026Price forecast
$7.00215.32%
Forecast & RatingStrong buy
4analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Aug 19 at 03:03 PM
Innate Pharma prices private placement of new shares at EUR 1.7 each
- Market Beat · Aug 14 at 02:02 PM
Innate Pharma Secures €30M, Extends Cash Runway Into 2028
- PUBT · Aug 14 at 11:33 AM
Bpifrance Participations, Innate Pharma board director, purchases EUR 3 million of Innate Pharma shares
- Quartr · Aug 14 at 09:45 AM
IPH: Three late-stage oncology assets drive value, with major partnerships and pivotal data due in H2 2026
- Quartr · Aug 14 at 07:05 AM
IPH: €30 million share offering priced, extending cash runway and funding clinical pipeline
- PUBT · Aug 14 at 04:30 AM
Innate Pharma schedules conference call and webcast
